- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Agios Pharm (AGIO)
Agios Pharm stock price live, this page displays NASDAQ AGIO stock exchange data. View the AGIO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Agios Pharm real time stock price chart below.
What Is the Agios Pharm Stock Price Today?
The Agios Pharm stock price today is 35.00.
What Is the Stock Symbol for Agios Pharm?
The stock symbol for Agios Pharm is ""AGIO.""
What Stock Exchange Does Agios Pharm Trade On?
Agios Pharm is listed and trades on the NASDAQ stock exchange.
Is Agios Pharm a Good Stock to Buy?
Determining whether Agios Pharm—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AGIO quote. (ISIN: US00847X1046)
What Is the Agios Pharm Stock Price Today?
The Agios Pharm stock price today is 35.00.
What Is the Stock Symbol for Agios Pharm?
The stock symbol for Agios Pharm is ""AGIO.""
What Stock Exchange Does Agios Pharm Trade On?
Agios Pharm is listed and trades on the NASDAQ stock exchange.
Is Agios Pharm a Good Stock to Buy?
Determining whether Agios Pharm—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AGIO quote. (ISIN: US00847X1046)
35.00
-2.22(-5.96%)
Closed·
After Hours
35.000.00(0.00%)
·
Fair Value
An estimate of a Agios Pharm's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
34.32
38.43
52 wk Range
23.42
62.58
AGIO Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
Fair Value
An estimate of a Agios Pharm's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
34.3238.43
52 wk Range
23.4262.58
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AGIO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Agios Pharm's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
50.00
Upside
+42.86%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Agios Pharm receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Agios Pharm receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 8K Agios Pharm For: 8 July
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Agios Pharm Company Profile
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Agios Pharm SWOT Analysis
Mitapivat's Promise | Explore Agios Pharmaceuticals' lead product, Pyrukynd (mitapivat), positioned as a first-in-class treatment for genetic diseases and cancer, driving stock momentum |
Financial Strength | Delve into Agios' robust financial position, with $1.7 billion cash reserve and strong liquidity, supporting ongoing R&D and future commercialization efforts |
Pipeline Potential | Learn about Agios' advancing clinical trials in sickle cell disease and thalassemia, with potential market launches and revenue projections reaching $540 million by 2033 |
Market Dynamics | Analyst price targets range from $51 to $57, reflecting optimism about Agios' market position amid shifting competitive landscapes in rare blood disorders |
Agios Pharm Earnings Call Summary for Q2/2025
- Q2 2025 EPS of -$1.93 missed forecast, but revenue of $12.5M beat expectations, up 45% YoY; stock fell 3.26% pre-market
- R&D expenses rose $14.5M and SG&A up $10.4M, reflecting investment in growth; company maintains strong balance sheet
- Focus on launching thalassemia treatment in US by September 2025; expects modest revenue growth for full year 2025
- CEO Brian Goff: '2025 is shaping up to be a breakout year,' highlighting strong pipeline and PK Activator franchise advancement
- Analysts inquired about ometipivat safety and pediatric thalassemia market readiness; no changes to safety profile reported
Last Updated: 31/07/2025, 15:18
Read Full TranscriptCompare AGIO to Peers and Sector
Metrics to compare | AGIO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAGIOPeersSector | |
|---|---|---|---|---|
P/E Ratio | 3.1x | −0.4x | −0.5x | |
PEG Ratio | 0.01 | −0.01 | 0.00 | |
Price/Book | 1.5x | 3.0x | 2.6x | |
Price / LTM Sales | 49.8x | 10.0x | 3.3x | |
Upside (Analyst Target) | 42.9% | 278.8% | 45.1% | |
Fair Value Upside | Unlock | 1.2% | 7.4% | Unlock |
Analyst Ratings
6 Buy
3 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 50.00
(+42.86% Upside)
Earnings
Latest Release
Jul 31, 2025
EPS / Forecast
-1.93 / -1.81
Revenue / Forecast
12.45M / 9.54M
People Also Watch
FAQ
What Stock Exchange Does Agios Pharm Trade On?
Agios Pharm is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Agios Pharm?
The stock symbol for Agios Pharm is "AGIO."
What Is the Agios Pharm Market Cap?
As of today, Agios Pharm market cap is 2.03B.
What Is Agios Pharm's Earnings Per Share (TTM)?
The Agios Pharm EPS (TTM) is 11.33.
When Is the Next Agios Pharm Earnings Date?
Agios Pharm will release its next earnings report on 29 Oct 2025.
From a Technical Analysis Perspective, Is AGIO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Agios Pharm Stock Split?
Agios Pharm has split 0 times.
How Many Employees Does Agios Pharm Have?
Agios Pharm has 487 employees.
What is the current trading status of Agios Pharm (AGIO)?
As of 04 Aug 2025, Agios Pharm (AGIO) is trading at a price of 35.00, with a previous close of 37.22. The stock has fluctuated within a day range of 34.32 to 38.43, while its 52-week range spans from 23.42 to 62.58.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.